BOCA RATON, Fla., March 7, 2017 /PRNewswire/ -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids, with superficial radiation therapy (SRT), today announced that Joe Sardano, the Company's chief executive officer, will present a corporate overview at the 29th Annual ROTH Conference on Wednesday, March 15th at 8:30 a.m. Pacific time. The conference will be held at the Ritz-Carlton, Laguna Niguel in Dana Point, Calif. from March 13th through 15th.
To listen to the presentation, investors may visit Sensus Healthcare's website at www.sensushealthcare.com or by clicking here.
An archived audio of the presentation and accompanying slides will also be available on the company's website for 90 days.
About Sensus HealthcareSensus Healthcare, Inc. is a medical device company that is committed to enabling non-invasive and cost-effective treatment of non-melanoma skin cancers and keloids. Sensus uses a proprietary low energy X-ray radiation technology known as superficial radiation therapy (SRT), which is a result of over a decade of dedicated research and development activities. Sensus has successfully incorporated the SRT therapy into its portfolio of treatment devices, the SRT-100™ and SRT-100 Vision™. To date, the SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions in thousands of patients.
For further information, please visit http://www.sensushealthcare.com
Contacts:Investors LHAKim Sutton Golodetz(212) [email protected]
Advertisement
To listen to the presentation, investors may visit Sensus Healthcare's website at www.sensushealthcare.com or by clicking here.
An archived audio of the presentation and accompanying slides will also be available on the company's website for 90 days.
Advertisement
About Sensus HealthcareSensus Healthcare, Inc. is a medical device company that is committed to enabling non-invasive and cost-effective treatment of non-melanoma skin cancers and keloids. Sensus uses a proprietary low energy X-ray radiation technology known as superficial radiation therapy (SRT), which is a result of over a decade of dedicated research and development activities. Sensus has successfully incorporated the SRT therapy into its portfolio of treatment devices, the SRT-100™ and SRT-100 Vision™. To date, the SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions in thousands of patients.
For further information, please visit http://www.sensushealthcare.com
Contacts:Investors LHAKim Sutton Golodetz(212) [email protected]
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/sensus-healthcare-to-present-at-the-29th-annual-roth-conference-300419374.html
SOURCE Sensus Healthcare, Inc.
